Biotechnology News and Research

RSS

EMA CHMP recommends conditional marketing authorization of FAMPYRA

The Committee for Medicinal Products for Human Use of the European Medicine Agency has recommended conditional marketing authorization of FAMPYRA (prolonged-release fampridine 10 mg tablets) for the improvement of walking in adult patients with multiple sclerosis with walking disability.

20 May 2011

EMA CHMP recommends positive opinion for marketing authorization of Amgen's XGEVA

Amgen today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended a positive opinion for the marketing authorization of XGEVA (denosumab) for the prevention of skeletal-related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with bone metastases from solid tumors.

20 May 2011

Accovion establishes new subsidiary in the UK

As a European full-service Clinical Research Organization, Accovion supports local and global projects of all types and phases for the Pharmaceutical, Biotechnology and Medical Device industries.

20 May 2011

VBL to present positive VB-111 preclinical data in metastatic lung cancer at 14th ASGCT

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced that it will present preclinical data demonstrating VB-111's potential synergy and additive therapeutic effect when administered in combination with the conventional chemotherapy cancer treatments.

20 May 2011

Unigene enters Clinical Manufacturing Services Agreement with Cara Therapeutics

Unigene Laboratories, Inc. a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced today that the Company signed a Clinical Manufacturing Services Agreement with Cara Therapeutics, Inc.

19 May 2011

Enzon to discontinue PEG-SN38 clinical program in metastatic colorectal cancer

Enzon Pharmaceuticals, Inc. today announced that, in light of evolving standards of care for the treatment of metastatic colorectal cancer (mCRC), the Company will discontinue its PEG-SN38 (EZN-2208) clinical program in this disease, following conclusion of its Phase II study.

19 May 2011

PolyMedix's PMX-30063 compound mitigates ulcerative mucositis in pre-clinical studies

PolyMedix, Inc., a biotechnology company focused on developing new therapeutic drugs to treat patients with acute infectious diseases and cardiovascular disorders, announced today that its lead defensin-mimetic antibiotic compound, PMX-30063, when administered topically as an oral rinse, has shown activity against oral mucositis in an animal study.

19 May 2011

RXi to present updated NeuVax Phase II trial data in breast cancer at ASCO 2011

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted and immunotherapy technologies, will be presenting data from the NeuVax Phase II adjuvant breast cancer clinical trial at the 2011 annual meeting of The American Society of Clinical Oncology in Chicago.

19 May 2011

Repligen receives approval from FDA to commence RG3039 Phase 1 trial in Spinal Muscular Atrophy

Repligen Corporation announced today that it has received approval from the Food and Drug Administration to initiate a Phase 1 clinical trial of RG3039, a potential treatment for Spinal Muscular Atrophy.

19 May 2011

ShangPharma first quarter net revenues increase 25.6% to $24.8 million

ShangPharma Corporation, a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced its financial results for its first quarter ended March 31, 2011.

19 May 2011

Affymetrix launches new Axiom myDesign TG Arrays for targeted genotyping market

Affymetrix, Inc. today launched new Axiom myDesign Targeted Genotyping (TG) Arrays for the targeted genotyping market, enabling researchers to study mutations in disease pathways and characterize gene-gene interactions.

19 May 2011

Low calorie sweeteners offer effective solution to manage weight

The desire to eat sweet things does not need to be suppressed, just managed, according to health and nutrition experts meeting at the International Sweeteners Association's conference in Brussels today.

19 May 2011

Silence to present new Atu027 Phase I study data in advanced solid tumors at ASCO annual meeting

Silence Therapeutics plc, a leading global RNA interference therapeutics company, announces that it will present new data from its ongoing Phase I study of Atu027, its lead internal therapeutic candidate, at the 2011 American Society of Clinical Oncology Annual Meeting on 06 June 2011.

19 May 2011

Metabolix initiates public offering of common stock

Metabolix, Inc., a bioscience company focused on developing sustainable solutions for plastics, chemicals and energy, today announced that it has commenced a public offering of shares of its common stock pursuant to the Company's effective shelf registration statement filed with the U.S. Securities and Exchange Commission.

19 May 2011

Mpex, Synteract partner for cystic fibrosis fundraising event

Synteract, Inc., a full-service, global contract research organization, and Mpex Pharmaceuticals, a biopharmaceutical company developing new therapies to combat the growing issue of antibiotic resistance, have partnered for the second annual Great Strides fundraiser to benefit cystic fibrosis.

19 May 2011

Biothera begins dosing in Imprime PGG and cetuximab combination Phase III trial for colorectal cancer

Biothera began dosing patients today in a Phase III trial evaluating Imprime PGG in combination with cetuximab as a potential new treatment for recurrent or progressive KRAS wild-type colorectal cancer.

19 May 2011

Affymetrix launches new menu of multiple genomic microarray tools

Affymetrix, Inc. today announced the availability of multiple genomic microarray tools that will further enable scientists in the applied research field.

18 May 2011

New data on personalized approaches for skin, ovarian and lung cancer to be presented at ASCO meeting

Genentech, a member of the Roche Group, today announced that data showing new personalized approaches for people with skin and lung cancer, plus new data with Avastin in ovarian cancer, will be presented at the 47th Annual Meeting of the American Society of Clinical Oncology.

18 May 2011

New book provides insight into new stem cell therapies for stabilizing heart function

A new book edited by researchers at Worcester Polytechnic Institute and the Stony Brook University School of Medicine provides a comprehensive look at the science and application of cellular therapies aimed at the leading cause of death---heart disease.

18 May 2011

JCO publishes Micromet's blinatumomab Phase 2 trial data in acute lymphoblastic leukemia

Micromet, Inc. today announced that data from a Phase 2 clinical trial of the Company's lead product candidate blinatumomab in patients with minimal residual disease positive acute lymphoblastic leukemia were published in the May 16th on-line edition of the Journal of Clinical Oncology.

18 May 2011

Biotechnology News and Research

EMA CHMP recommends conditional marketing authorization of FAMPYRA

EMA CHMP recommends positive opinion for marketing authorization of Amgen's XGEVA

Accovion establishes new subsidiary in the UK

VBL to present positive VB-111 preclinical data in metastatic lung cancer at 14th ASGCT

Unigene enters Clinical Manufacturing Services Agreement with Cara Therapeutics

Enzon to discontinue PEG-SN38 clinical program in metastatic colorectal cancer

PolyMedix's PMX-30063 compound mitigates ulcerative mucositis in pre-clinical studies

RXi to present updated NeuVax Phase II trial data in breast cancer at ASCO 2011

Repligen receives approval from FDA to commence RG3039 Phase 1 trial in Spinal Muscular Atrophy

ShangPharma first quarter net revenues increase 25.6% to $24.8 million

Affymetrix launches new Axiom myDesign TG Arrays for targeted genotyping market

Low calorie sweeteners offer effective solution to manage weight

Silence to present new Atu027 Phase I study data in advanced solid tumors at ASCO annual meeting

Metabolix initiates public offering of common stock

Mpex, Synteract partner for cystic fibrosis fundraising event

Biothera begins dosing in Imprime PGG and cetuximab combination Phase III trial for colorectal cancer

Affymetrix launches new menu of multiple genomic microarray tools

New data on personalized approaches for skin, ovarian and lung cancer to be presented at ASCO meeting

New book provides insight into new stem cell therapies for stabilizing heart function

JCO publishes Micromet's blinatumomab Phase 2 trial data in acute lymphoblastic leukemia

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News